Navigation Links
Questcor Pharmaceuticals Expands Repurchase Program
Date:5/16/2012

, were driven by our belief that there is a substantial difference between the intrinsic value and the market value of our common stock.  This belief is based on several factors, including the following:

  • Net sales and earnings per share for the quarter ended March 31, 2012 increased by more than 60% over the quarter ended September 30, 2011 – the quarter prior to the initial expansion of our nephrotic syndrome sales force from 5 to 28 Acthar specialists;
  • We have gained greater confidence in the long-term potential for Acthar in the treatment of patients suffering from nephrotic syndrome;
  • We are in the process of further expanding our nephrology and neurology sales forces, and similar expansions in the past have resulted in significant growth in net sales; and
  • We are preparing to launch a pilot effort in rheumatology, a therapeutic area in which Acthar has a number of approved indications with sizeable markets with patients with high unmet needs.

From the beginning of 2008 through May 15, 2012, we have returned approximately 78% of our operating cash flow to shareholders by repurchasing stock at an average price of $12.26 per share.  During that period, we have also been able to fund other important initiatives, including the significant expansion of our research and development activities.  We have also continued our patient-support programs, providing $150 million in free Acthar through March 31, 2012. "

Stock repurchases under this program may be made through open market or privately negotiated transactions in accordance with all applicable laws, rules and regulations. The transactions may be made from time to time and in such amounts as management deems appropriate. The number of shares to be repurchased and the timing of repurchases will be based on several factors, including the price of the Company's common stock, general business and market condi
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
3. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
4. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
5. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
6. Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
7. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
8. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
9. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
10. Syndax Pharmaceuticals Appoints Arlene Morris as CEO
11. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... LANSING, Mich. , March 27, 2015  Neogen ... Properties, LLC, has adopted a prearranged trading plan in ... James Herbert , Chairman and CEO of Neogen Corporation, ... shares of Neogen Corporation common stock. Herbert ... the disclosure was appropriate. The filing is only for ...
(Date:3/27/2015)... , March 27, 2015  CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... and 12 months ended December 31, 2014.  ... million), or ($0.05) per share, for the three months ...
(Date:3/26/2015)... The Market Element LLC, a leading inbound ... Designing Gig LLC to provide website design, development, and ... this alliance with Designing Gig represents a pivotal moment ... comprehensive, end-to-end, digital solution for our clients, which now ... Miller, president of The Market Element. “For small and ...
(Date:3/26/2015)... 26, 2015 ReliantHeart, Inc., an innovative ... a supplier of precision transit-time flow measurement solutions, are ... improve the efficiency of the HeartAssist5® Left ... to experience greater mobility and peace of mind. ... flow board, will draw 1/6th of the power required ...
Breaking Biology Technology:Neogen CEO adopts 10b5-1 Trading Plan 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... 4 /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin ... company in the People,s Republic,of China, today announced ... its common stock which will begin trading under ... Genesis, common stock will no longer trade,under the ...
... Shandong, China, Sept. 4 /Xinhua-PRNewswire-FirstCall/ --,China Biologic ... Biologic",or the "Company"), one of the leading ... China (the "PRC"), today announced that on,August ... Drug Administration (the "SFDA"),granted China Biologic,s production ...
... EDMONTON, Sept. 4 /PRNewswire-FirstCall/ - BioMS Medical Corp. ... multiple sclerosis (MS), today,announced that the Food and ... fast track designation for the Company,s lead drug, ... (SPMS). Dirucotide,(MBP8298) is currently being evaluated in a ...
Cached Biology Technology:Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol 2Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol 3China Biologic's Production Facility Renews GMP Certification 2China Biologic's Production Facility Renews GMP Certification 3BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 2BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 3BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 4
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
(Date:3/23/2015)... 23, 2015   HOYOS Labs , a leading ... announced that the Company will demonstrate multiple biometrics-based technologies ... consumers at Connect:ID on March 23 through 25, 2015, ... will highlight the IEEE Biometric Open Protocol Standard; free ... enterprise access control system. BOPS was invented by HOYOS ...
(Date:3/20/2015)... 2015 Research and Markets ( ... "India Sensors Market Forecast and Opportunities 2020" ... sensor market is projected to grow at a ... electronics, automotive, industrial and healthcare sectors are the ... In addition, adoption of MEMS technology in sensors ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... and Shenzhen, China, September 30, 2013 - China,s genomics ... the initiation of a joint project to unravel the ... of over $900k, the project will be one of ... involve experts from the IPATIMUP, a leading cancer research ...
... Pace recognizes that we are at a critical time in ... decrease in new HIV infections worldwide and increasing numbers of ... and vaccine research and new evidence on Treatment as Prevention, ... Sharon Lewin, Local Co-Chair of AIDS 2014, Head of the ...
... the human body, particularly neuroproteins that maintain proper brain ... and Parkinson,s are known as "tangle diseases" because they ... in the brain. A team of Australian and ... BMAA can be inserted into neuroproteins, causing them to ...
Cached Biology News:New mechanism for protein misfolding may link to ALS 2
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
Request Info...
Candida (IgG) -Ab EIA Sample Size: 5 l...
... (Competitive) EIA Principle: The Oxidized LDL ... 4E6. Oxidized LDL in the sample competes with ... the microtiter well for the binding of the ... Sample Size: 25 l The Oxidized ...
Biology Products: